NASDAQ:UTHR United Therapeutics (UTHR) Stock Forecast, Price & News $222.75 -0.93 (-0.42%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$221.82▼$225.0050-Day Range$217.48▼$248.2452-Week Range$202.31▼$283.09Volume163,675 shsAverage Volume232,435 shsMarket Capitalization$10.45 billionP/E Ratio12.60Dividend YieldN/APrice Target$296.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability United Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside33.1% Upside$296.44 Price TargetShort InterestHealthy2.32% of Shares Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.95Based on 7 Articles This WeekInsider TradingSelling Shares$6.07 M Sold Last QuarterProj. Earnings Growth9.34%From $18.95 to $20.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.14 out of 5 starsMedical Sector15th out of 965 stocksPharmaceutical Preparations Industry5th out of 456 stocks 3.4 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 8 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $296.44, United Therapeutics has a forecasted upside of 33.1% from its current price of $222.75.Amount of Analyst CoverageUnited Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.32% of the outstanding shares of United Therapeutics have been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently decreased by 42.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 3.3 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for United Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows6 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,074,499.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 9.34% in the coming year, from $18.95 to $20.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 12.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.90.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 12.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 99.71.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About United Therapeutics (NASDAQ:UTHR) StockUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comPaul A. Mahon Sells 6,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockSeptember 22, 2023 | finance.yahoo.comUnited Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation ProgramsSeptember 24, 2023 | Stansberry Research (Ad)New gold-backed currency could kill the DollarRumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the priceSeptember 18, 2023 | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells $85,163.88 in StockSeptember 12, 2023 | finance.yahoo.comUnited Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit ReportSeptember 9, 2023 | finance.yahoo.comEVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics CorpSeptember 5, 2023 | bizjournals.comFederal judge dismisses sexual harassment lawsuit against United Therapeutics and top execsSeptember 4, 2023 | finance.yahoo.comHere's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention TodaySeptember 24, 2023 | Stansberry Research (Ad)New gold-backed currency could kill the DollarRumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the priceAugust 3, 2023 | msn.comWedbush Maintains United Therapeutics (UTHR) Outperform RecommendationAugust 3, 2023 | msn.comHC Wainwright & Co. Reiterates United Therapeutics (UTHR) Buy RecommendationAugust 3, 2023 | msn.comUnited Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than JustifiedAugust 3, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Their Sell Rating for United Therapeutics (UTHR)August 2, 2023 | finance.yahoo.comUnited Therapeutics (UTHR) Tops Q2 Earnings and Revenue EstimatesAugust 2, 2023 | finance.yahoo.comUnited Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesAugust 2, 2023 | finance.yahoo.comUnited Therapeutics Corporation Reports Second Quarter 2023 Financial ResultsJuly 26, 2023 | finance.yahoo.comUnited Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023July 25, 2023 | bizjournals.comUnited Therapeutics claims victory in patent infringement suit against LiquidiaJuly 24, 2023 | markets.businessinsider.comGoldman Sachs Remains a Sell on United Therapeutics (UTHR)July 24, 2023 | finance.yahoo.comUnited Therapeutics Wins Appeal in Dry Powder Inhaler Patent LitigationJuly 10, 2023 | finance.yahoo.comUnited Therapeutics (NASDAQ:UTHR) sheds 5.3% this week, as yearly returns fall more in line with earnings growthJune 23, 2023 | msn.comLiquidia: Ready To Start A Stream Of Revenue For InvestorsJune 14, 2023 | bizjournals.comUnited Therapeutics to build $500M manufacturing facility in RTPJune 14, 2023 | finance.yahoo.comUnited Therapeutics Unveils Net Zero Energy Distribution CenterJune 8, 2023 | finance.yahoo.comWhy Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?May 16, 2023 | bizjournals.comUnited Therapeutics’ Revivicor advancing Virginia manufacturing facility for pig organsMay 4, 2023 | msn.comLadenburg Thalmann Maintains United Therapeutics (UTHR) Buy RecommendationSee More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Company Calendar Last Earnings8/02/2023Today9/24/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees985Year Founded1996Price Target and Rating Average Stock Price Forecast$296.44 High Stock Price Forecast$375.00 Low Stock Price Forecast$230.00 Forecasted Upside/Downside+33.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$17.68 Trailing P/E Ratio12.60 Forward P/E Ratio11.75 P/E GrowthN/ANet Income$727.30 million Net Margins41.29% Pretax Margin52.98% Return on Equity17.52% Return on Assets14.03% Debt Debt-to-Equity Ratio0.15 Current Ratio8.68 Quick Ratio8.40 Sales & Book Value Annual Sales$1.94 billion Price / Sales5.40 Cash Flow$17.08 per share Price / Cash Flow13.04 Book Value$105.24 per share Price / Book2.12Miscellaneous Outstanding Shares46,930,000Free Float41,066,000Market Cap$10.45 billion OptionableOptionable Beta0.62 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 68)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 51)Pres & COO Comp: $2.83MMr. James C. Edgemond (Age 55)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 59)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate VP of HRKevin T. GraySr. VP of Strategic Operations & LogisticsMr. Patrick Poisson (Age 55)Exec. VP of Technical Operations Dr. Leigh PetersonSr. VP of Product Devel.Mr. Gil GoldenSr. VP & Chief Medical OfficerMore ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSAlkermesNASDAQ:ALKSImmunoGenNASDAQ:IMGNAmicus TherapeuticsNASDAQ:FOLDMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsBarclays PLCBought 44,715 shares on 9/21/2023Ownership: 0.188%Paul A MahonSold 6,000 sharesTotal: $1.33 M ($222.19/share)Nilda MesaSold 383 sharesTotal: $85,163.88 ($222.36/share)Paul A MahonSold 6,000 sharesTotal: $1.34 M ($222.98/share)Alberta Investment Management CorpBought 9,868 shares on 8/24/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions UTHR Stock - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price forecast for 2023? 9 brokers have issued 1 year target prices for United Therapeutics' shares. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they predict the company's stock price to reach $296.44 in the next year. This suggests a possible upside of 33.1% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2023? United Therapeutics' stock was trading at $278.09 at the start of the year. Since then, UTHR stock has decreased by 19.9% and is now trading at $222.75. View the best growth stocks for 2023 here. Are investors shorting United Therapeutics? United Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,090,000 shares, a decline of 42.3% from the August 15th total of 1,890,000 shares. Based on an average daily volume of 332,900 shares, the short-interest ratio is currently 3.3 days. View United Therapeutics' Short Interest. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported $5.24 earnings per share for the quarter, beating the consensus estimate of $4.57 by $0.67. The biotechnology company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $524.18 million. United Therapeutics had a net margin of 41.29% and a trailing twelve-month return on equity of 17.52%. United Therapeutics's quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.41 earnings per share. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Inspire Faithward Mid Cap Momentum ETF (GLRY), Formidable Fortress ETF (KONG), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Intelligent - Large Cap Value ETF (AILV). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). What is United Therapeutics' stock symbol? United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR." Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.86%), Renaissance Technologies LLC (4.66%), State Street Corp (4.00%), Geode Capital Management LLC (1.72%), Bank of New York Mellon Corp (1.27%) and Dimensional Fund Advisors LP (1.14%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is United Therapeutics' stock price today? One share of UTHR stock can currently be purchased for approximately $222.75. How much money does United Therapeutics make? United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.45 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $17.68 on an earnings per share basis. How many employees does United Therapeutics have? The company employs 985 workers across the globe. How can I contact United Therapeutics? United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291. This page (NASDAQ:UTHR) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.